Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)

Inclusion Criteria: * Male and female healthy volunteers (ages 18-55 years) and patients with CHD (ages 18 to 75 years) on stable statin therapy for at least 8 weeks, with normal liver and kidney function. * Women who are post-menopausal, surgically sterile, or practicing effective contraception. Additional birth control details to be provided at screening. * Body mass index (BMI) must be within the range of 20 to 35 for CHD patients or CHD equivalents. * Clinical CHD: * Myocardial infarction (MI), angina, revascularization (e.g. CABG, stent) at least 6 months prior to inclusion * CHD equivalents: * symptomatic carotid artery disease (e.g. transient ischemic attack or stroke of carotid origin) or peripheral artery disease or abdominal aortic aneurysm or Diabetes Mellitus (HbA1c ≤9) * 20% 10 year risk of CHD (Framingham point score: ≥16 (men), ≥23 (women)) * Other clinical forms of atherosclerotic disease including \>50 percent stenosis on angiography or ultrasound * Male subjects, when sexually active, using one form of highly effective contraception (e.g. condom) Exclusion Criteria for both healthy volunteers and patients: * Smokers (use of tobacco products in the previous 3 months). Smokers who report cigarette use of more then 10 cigarette per day or have a urinary cotinine level greater then 500 ng/ml. * Pregnancy. * Use of any prescription drugs within four (4) weeks prior dosing, or over-the-counter (OTC) medication (vitamins, herbal supplements, dietary supplements) within two (2) weeks prior to dosing. Significant illness within two weeks prior to dosing. * Significant illness within two weeks prior to dosing. * A past medical history of clinically significant ECG abnormalities or a family history of a prolonged QT-interval syndrome. * History of clinically significant drug allergy or history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known hypersensitivity to the study drug or drugs similar to the study drug or any allergic reaction to prior receipt of protein therapies or vaccines. * Presence of NYHA Class III or IV CHF or unstable angina pectoris. * MI or within angioplasty (including stenting), acute coronary syndrome (ACS), unstable angina or arterial embolic disease within 6 months prior to dosing. * Use of certain medications prohibited by the protocol. * Uncontrolled diabetes (HbA1c \> 9). * Uncontrolled hypertension (Systolic BP \>160 mm Hg and/or Diastolic BP \>100 mmHg on two consecutive measurements). * Liver or kidney disease confirmed by abnormal lab values or function. * Serum creatine kinase CK (CPK) total \> 2x. * CHD equivalent patients with a history of early positive exercise stress test. Other protocol-defined inclusion/exclusion criteria may apply